Advertisement

Drugs in R & D

, Volume 2, Issue 3, pp 211–212 | Cite as

Lyme Disease Vaccine (Pasteur Mérieux Connaught)

ImuLyme™
Section 2: Prophylactic Anti-Infective Vaccines Adis R&D Profile
  • 6 Downloads

Keywords

Lyme Disease Borrelia Burgdorferi Injection Site Pain Outer Surface Protein Lyme Disease Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Clinical trial demonstrates Pasteur Mérieux Connaught’s candidate Lyme disease vaccine reduces overall occurrence of lyme disease in participants. [press release]. Pasteur Mérieux Connaught [online]: 1997 Sep 15. Available from: URL: http://www.us.pmc-vacc.com [Accessed 1999 Sep 3]
  2. 2.
    Sigal LH, Zahradnik JM, Lavin P, et al. Avaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N Engl J Med 1998 Jul 23; 339: 216–22PubMedCrossRefGoogle Scholar
  3. 3.
    Wormser GP, Nowakowski J, Nadelman RB, et al. Efficacy of an OspA vaccine preparation for prevention of lyme disease in New York State. Infection 1998 Jul–Aug; 26: 208–12PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Personalised recommendations